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Introduction
Curative resection is the treatment of choice in localised
primary and metastatic liver tumours. Following operation
for hepatocellular carcinoma in selected patients, the 5-
year survival rate can approach 70% [1] and the 5-year
disease-free rate 38% [2]. Resection of liver with localised
metastatic disease can also produce impressive results
for both colorectal neoplasms [3] and non-colorectal
malignancies [4].
Estimation of postoperative liver function is problem-
atic as dynamic tests of hepatic clearance of indocyanine
green do not give either the maximum amount of liver that
can be resected or the functional capacity of the liver that
will remain. Futhermore, since the actual volume needed
varies between individuals and with the state of the hepatic
parenchyma, no absolute minimal volume of liver needed
to function can be stated. Up to 60% of a normally func-
tioning liver may be resected [5]. Large localised tumours
may be considered inoperable if the future liver remnant is
too small for adequate postoperative functioning. This
problem is amplified if there is accompanying liver
parenchymal disease. Whole liver volume and the volume
of segments remaining after resection can be accurately
measured by either computerised tomography [6] or
magnetic resonance imaging [7].
Various efforts have been made to overcome the prob-
lem of inadequate postoperative liver volume. For small
hepatocellular tumours, transplanting the liver can produce
3-year [8] and 5-year [9] survival figures comparable to or
better than those of liver resection. However, transplant
options are severely limited by the acute shortage of organs.
Furthermore, transplantation is not a suitable option for
metastases or large primary tumours.
An alternative strategy is to increase preoperative liver
volume by attempting to induce compensatory hypertrophy
of the non-involved segments. This manouevre is achieved
Preoperative portal vein embolisation for primary
and metastatic liver tumours: volume effects,
efficacy, complications and short-term outcome
K Seymour, RM Charnley, JDG Rose, CJ Baudouin and D Manas
HPB Surgery Unit and Department of Radiology, Freeman Hospital, High Heaton, Newcastle upon Tyne, NE7 7DN
Background
The aim of portal vein embolisation is to induce hyper-
plasia of normal tissue when resection of a cancerous
portion of the liver is contraindicated only by the volume
of liver that would remain following operation.
Methods
Eight patients with inoperable liver tumours (3 women and
5 men, median age 69.5 years, 3 colorectal hepatic metas-
tasts,2 choloangiocarcinoma s and 3 hepatocellula r cancers)
were selected for portal vein embolisation . Selected portal
branches were occluded with microparticles and coils.Liver
volumes were determined by magnetic resonance imaging
(MRI) before embolisation and again before operation.
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Embolisation was successfully performed in all 8 patients,
7 by the percutaneous-transhepatic route, while one
patient required open cannulation of a mesenteric vein.
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‘curative’ resection; projected remaining liver volumes
increased (Wilcoxon’s matched pairs test p = 0.02) from a
median of 361 cc to a median of 550 cc; two patients had
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indicated. In one patient a misplaced coil unintentionall y
occluded a portal branch to normal liver.
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Portal vein embolisation produced appreciable hyperplasia
of the normal liver and extended the option of ‘curative’
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Complications can occur. The long-term results following
operation are unknown.
Keywords
liver neoplasms; imaging; portal vein; embolisation
Correspondence to: keithhelen@fsmail.net
HPB 2002 Volume 4, Number 1 21–28
© 2002 Martin Dunitz Ltd.
Martin Dunitz Taylor&Francishealthsciences
by inducing ischaemia of the area of the liver to be removed
by occluding its blood supply. In this regard embolisation of
the hepatic artery has not been effective in hepatocellular
carcinoma and only occasionally allows a change in the
operative intention for the patient [10]. Indeed the surgical
outcome has been shown to be worse by some authors
following this intervention [11].
Preoperative portal vein embolisation (POPE) has
shown more promise. Its main potential benefit is induc-
tion of liver hypertrophy to extend the limits of resection.
It may also limit centripedal extension of tumour thrombus,
prevent dissemination of the tumour cells via the portal
vein and possibly (if combined with arterial embolisation)
cause complete ischaemic necrosis of the tumour [12].
POPE has been successfully performed for primary liver
cancers [13] and metastatic liver tumours [14] in both
normal and cirrhotic livers [15].
In this paper we present a small experience of POPE in
eight patients in liver volumes before ‘curative’ resection
with measurements of the changes in liver volumes.
Patients and Methods
Patients were selected for POPE after review by 2
experienced surgeons if they had a liver tumour that was
potentially curable by resection and if operation was
contraindicated by the size of the future liver remnant
calculated from preoperative imaging. Liver volumes and
the volumes of uninvolved segments were calculated from
staging magnetic resonance imaging, as described by
Caldwell [7].
Eight patients with inoperable liver tumours were
selected for portal vein embolisation (details summarised in
Table 1). There were 3 women and 5 men of median age
69.5 years (range 38–74 years). POPE was performed for
colorectal hepatic metastases in 3 patients, choloangiocar-
cinoma in two and hepatocellular cancer in 3 patients.
All patients were initially referred for percutaneous
embolisation. POPE was performed using a method devel-
oped from that previously described by Kinoshita [16].
Informed consent was obtained from each patient, and the
procedure was performed under light sedation and local
anaesthetic. Under ultrasound guidance, a fine needle
(22G) was passed percutaneously from the epigastrium
through the liver into a branch of the portal vein. Areas
of tumour involvement were avoided to prevent needle
track dissemination. After securing the punctured portal
venous segment with a 018 guidewire, the needle was
removed over the wire. A coaxial dilating system (NEFF
set, Win Cook UK, St Albans, Herts) was used to dilate
the track over the wire. The wire was exchanged through
the dilator for a standard 035 guidewire and a 5F vascular
sheath was inserted. A curved angio catheter, usually a
‘cobra’ shape, was then used to access the main portal vein
and perform preliminary portal venography. From here
the catheter was steered into position so that the selected
branches could be embolised. Individual segmental vessels
were occluded distally with polyvinylalcohol particles
(Contour) and proximally with suitably sized coils deter-
mined by the vessel diameter (Figure 1). The change in
volume of each patient’s liver was calculated from sectional
magnetic resonance imaging (MRI) obtained before and
after embolisation. The first volume measurements were
calculated from the initial staging MRI. Follow-up scans
were performed at four weekly intervals until hypertrophy
of the liver permitted safe operation. A two-tailed
Wilcoxon’s matched pairs test was used to compare the
size of the ‘residual’ liver before and after embolisation.
The location of the tumours and the segments embolised
are summarised in Table 1.
Results
Embolisation was successfully performed in 7 patients by
the percutaneous-transhepatic route. One other patient
required an open cannulation of the inferior mesenteric
vein because a large tumour prevented safe access to the
portal vein via the percutaneous route. One patient (no. 1)
had POPE attempted via an ipsilateral approach which
failed to give access to all the segments selected for emboli-
sation. A contralateral approach one week later successfully
completed the embolisation procedure.
Liver volumes and patient outcome
Liver volumes were calculated from MRI obtained in a
single breath-hold before and after the procedure in all
patients. The projected remaining liver volumes increased
from a median of 361 cc (range 250–578 cc) to a median of
550 cc (range 329–703 cc). (Wilcoxon’s matched pairs test
p = 0.02.)
Management was altered in 6 patients (75%) who pro-
ceeded to ‘curative’ operation following the induced liver
(predominantly left lobe) hypertrophy (Figure 2). The
other 2 patients (25%) developed disease progression so
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that liver resection was no longer indicated. The outcome
and survival of patients following POPE are summarised in
Table 1.
Complications
Complications occurred in 2 of the 8 patients (25%). There
were no deaths due to the procedures and there were no
instances of ‘post-embolisation syndrome’. One patient
(no. 1) developed a subcapsular haematoma that was suc-
cessfully managed conservatively. One patient (no. 8), with
a hilar bile duct cancer had his left portal branch uninten-
tionally occluded by a misplaced coil that was successfully
retrieved, but the left portal branch remained occluded.
However, it was noted that flow in the left portal branch
vessel was poor before the start of the embolisation. Despite
this complication he did not develop abnormal liver func-
tion tests or a post-embolisation syndrome, but the left lobe
did atrophy. He underwent laparotomy and trial dissection
but the tumour was inoperable, invading second order bile
ducts on both the right and left sides of the liver.
Discussion
Since the first early experiences of portal vein embolisation
in the 1980s [13], many authors have reported its use for
hepatocellular carcinomas. Experience of its use in other
tumours is very limited, with fewer than 10 cases reported in
metastatic cancers [14,17,18]; these may include repeated
K Seymour et al.
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Figure 2. Magnetic resonance images showing (a) the tumour in the right lobe and a small left lobe prior to embolisation and (b) the corresponding scan after
embolisation showing left lobe hypertrophy. Note the region of the upper pole of the right kidney for orientation of level.The appreciable hypertrophy is noted one
month following embolisation.
Figure 1. Catheter angiograms showing (a) portal venous anatomy and (b) the occluding coils in the liver and occlusion of the portal branches to the right lobe of
the liver after embolisation.
publication of different aspects of the same cases. Similarly,
experience is limited in bile duct carcinoma [19–21].
Various materials can be used to occlude the portal vein
including alcohol [22], fibrin glue [23], lipiodol [24],
gelfoam, gelatin sponges [25], cyanoacrylate and coils [26].
There is no evidence for superior effectiveness of any of
them, and each has its exponents. Computed tomography
(CT) [6] and magnetic resonance imaging (MRI) [7] can
both provide accurate measurements of in vivo liver vol-
umes. To achieve accurate volume measurements from MRI
and CT images the scans should be obtained in a single
breath-hold. Fast machines are therefore desirable.
In this series the success rate of portal vein embolisation
in altering patient managment was 75%. This figure is
lower than, but comparable to, other reports: de Baere [25]
reports success in 9/10 patients attempted and Elias [27]
reports an 82% (23/28) resection rate following POPE.
There were two ‘failures’ in this series associated with
disease progression. The principles behind POPE raise
oncological concerns. After embolisation an area of liver is
made ischaemic, which leads to increased portal blood flow
to the other segments of the liver not embolised [28] and
possibly a paracrine or endocrine response that eventually
results in hypertrophy of the remaining liver as the desired
effect. During liver regeneration high levels of growth
factors including transforming growth factor- a and hepato-
cyte growth factor are found, and these mediate the regen-
eration [29]. These growth factors are also tropic to tumour
cells, and it is known that liver regeneration per se acceler-
ates the growth of colon tumour cells [30]. Indeed Elias [18]
has recently observed apparent accelerated metastatic
tumour growth in livers undergoing POPE. For these
reasons, use of this procedure should be limited to those
patients for whom this method offers the only chance of
cure. It should be borne in mind that these patients face a
bleak alternative, and the same effects are possible after any
resection of the liver when regeneration occurs and when
micro-metastases are present. This fact does not prevent
benefit from such resections, but it does seem prudent to
minimise the interval between POPE and resection to
reduce the risk of progression. Furthermore, this feature of
accelerated growth may unmask occult tumour in segments
previously thought to be disease-free and may prevent a
resection that would not have been of any benefit to the
patient. Patients in this series had operations carried out
4–11 weeks following embolisation. Because of the small
number of patients world-wide suitable for this interven-
tion, randomised trials of outcome to resolve the oncological
concerns are not practical.
A serious complication of POPE that was noted in this
series was a misplaced coil that occluded the left portal vein
(to the lobe intended to remain). This occlusion did not
result in any detectable clinical symptoms or biochemical
disturbance, but was associated with disease progression
and atrophy of the left lobe. Bleeding causing a subcapsular
haematoma and phrenic irritation was also noted on one
occasion. Fortunately the bleeding was not severe and did
not require intervention. These complications do raise
dilemmas over the most appropriate approach to the portal
vein. There are three possibilities: 1) An approach on the
same side as the tumour, in which the contralateral vein is
not compromised, but the needle track may be close to the
tumour with the attendant risk of dissemination. In addi-
tion the ipsilateral procedure may be technically more
difficult because of the need to steer acute angles in the
portal system. 2) The contralateral approach which may
reduce the risk of tumour seeding, but the vein intended to
remain has been traumatised and haemorrhagic complica-
tions may be more difficult to manage in liver that should
be preserved. 3) It is possible (performed once in this series)
to place the catheters into mesenteric vessels surgically,
thus avoiding the potential problems of either of the other
approaches; this may be the method of choice.
It is of interest to note that tumour progression occurred
for each cholangiocarcinoma rather than the hepatocellu-
lar cancers or colorectal hepatic metastases, but numbers
are too small to attach any meaning to this observation.
Although we have provided follow-up data, the length of
follow-up is short. Therefore no conclusions about benefit
of this intervention can be made at this stage.
In summary, portal vein embolisation produced marked
hypertrophy of the normal liver and extended the option of
‘curative’ surgery to 6 out of 8 patients. It appears to be equally
effective for primary and metastatic liver tumours in selected
patients. Complications can and do occur. An approach to
the portal vein via a mesenteric vessel has potential advan-
tages over the percutaneous transhepatic routes. Concerns
about the adverse oncological effects of this procedure mean
that in the absence of an alternative with good curative or
palliative results, its use should be limited to selected cases
for whom the prognosis is otherwise hopeless. The shortest
time interval between embolisation and operation is desir-
able rather than maximum hypertrophy. Reports on the
long-term results of operation are needed in these patients.
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Commentary
In this well-performed clinical study the authors have
treated 8 patients with initially inoperable liver tumours by
means of portal vein embolisation. Selected portal
branches were occluded with microparticles and coils by
percutaneous transhepatic route in 7 patients and by open
embolisation in one. This type of preoperative therapy
should be considered in patients fit for operation but with
tumour load beyond resectability. The authors also give
advice on different ways of achieving portal vein embolisa-
tion, and they state that the transhepatic percutaneous
route is the one to be preferred.
One serious problem with this approach is of course the
effect on tumour growth, which the authors rightly address.
The response to portal vein embolisation is vigorous, and
the general response equals that of liver resection in terms
of regeneration (1). It induces atrophy in the embolised
liver segment. There is ample evidence from the literature
that tumour growth is stimulated in experimental systems
during the regenerative process, and apparently similar
growth stimuli will affect both normal liver and tumour (2).
This may be a problem if micrometastases are present in the
nonoccluded parts of the liver. However, this effect must be
weighed against the bleak outcome for the patient left
untreated. One way of diminishing this risk is to keep the
length of time between embolisation and operation as short
as possible. The authors in this study waited 4–11 weeks.
This time interval seemed long enough to induce liver
regeneration and short enough not to affect tumour growth.
As tumour growth and liver growth seem to be affected by
similar stimuli, this is an area of research that should be
explored further to increase our knowledge of tumour
growth in the liver.
As the authors point out in their discussion, the
indications for preoperative embolisation will be limited
to only a few patients in each centre, and it is therefore
difficult to perform a randomised trial. Nevertheless, there
are enough data to recommend that preoperative portal
embolisation should be used in selected cases of
irresectable liver tumours.
Professor BW Jeppsson
Department of Surgery
Malmö University Hospital
Malmö
Sweden
S-205 02
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Commentary
Mr Seymour and his colleagues report here their experience
of a small series of patients submitted to portal vein
embolization (PVE) before liver resection for primary and
metastatic liver tumours, primarily considered as irre-
sectable due to the insufficient size of the future remnant
liver.
This series clearly illustrates the two limitations of this
technique that might preclude liver resection; (i) technical
errors during portal embolisation and (ii) disease progres-
sion in the interval before liver resection.
l To avoid unintentional contralateral portal emboli-
sation, the use of an occlusive balloon (1,2) or a dif-
ferent embolic agent (such as glue mixed with
lipiodol) allows better fluoroscopic visualisation and
better control of the embolisation process (3).
l The disease progression during the interval between
PVE and liver resection should be prevented by the
administration of adjuvant therapy, e.g. arterial
chemo-embolisation at least three weeks before PVE
in patients with hepatocellular carcinoma (1,2), or
adjuvant chemotherapy (such as 5 fluoro-uracil and
folinic acid with oxaliplatine) in patients suffering
from colorectal liver metastases (2). By using this
strategy, we observed a significant decrease of liver-
metastatic disease at the time of liver resection six-
to-eight weeks later.
The criteria for selecting the patients undergoing PVE
are unclear in this series. In fact, the definition of insuffi-
cient liver remnant varies between the different published
series (1,2,3–5). While the relative volume of the remnant
liver is the most important criterion, other factors such as
active hepatitis B carriage, presence of liver cirrhosis, liver
steatosis or steatofibrosis and a previous history of arterial
chemo-embolisation or multiple courses of neoadjuvant
chemotherapy, should also be taken into consideration.
The respective weight of these factors remains difficult to
evaluate.
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Since the complication rate of PVE is negligible in our
initial personal experience of 22 patients (6), we are now
performing PVE for all patients with a future liver remnant
volume less than 25% of the whole liver in the absence of
the above risk factors. The volume of the residual func-
tional liver parenchyma should always be calculated by sub-
tracting the volume of liver tumours. In addition, the liver
volume measurement should be performed by the same type
of radiological investigation (preferably magnetic reso-
nance imaging technique in our experience) due to the
imperfect reproducibility of such calculation with different
imaging techniques.
Finally, there is no doubt that PVE is a major advance
in the management of the patient with extensive
malignant primary or metastatic liver diseases. A multidis-
ciplinary approach with interventional radiologists allows
optimal care for the patients.
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